KR102655779B1 - 콘드로이틴 황산 유도체 및 방광 질환 처치제 - Google Patents

콘드로이틴 황산 유도체 및 방광 질환 처치제 Download PDF

Info

Publication number
KR102655779B1
KR102655779B1 KR1020237009204A KR20237009204A KR102655779B1 KR 102655779 B1 KR102655779 B1 KR 102655779B1 KR 1020237009204 A KR1020237009204 A KR 1020237009204A KR 20237009204 A KR20237009204 A KR 20237009204A KR 102655779 B1 KR102655779 B1 KR 102655779B1
Authority
KR
South Korea
Prior art keywords
group
steroid
spacer
bladder
chondroitin sulfate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020237009204A
Other languages
English (en)
Korean (ko)
Other versions
KR20230047193A (ko
Inventor
무네토 나리타
다카히로 하타나카
유코 요시다
Original Assignee
세이가가쿠 고교 가부시키가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 세이가가쿠 고교 가부시키가이샤 filed Critical 세이가가쿠 고교 가부시키가이샤
Publication of KR20230047193A publication Critical patent/KR20230047193A/ko
Application granted granted Critical
Publication of KR102655779B1 publication Critical patent/KR102655779B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/554—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being a steroid plant sterol, glycyrrhetic acid, enoxolone or bile acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C08B37/0069—Chondroitin-4-sulfate, i.e. chondroitin sulfate A; Dermatan sulfate, i.e. chondroitin sulfate B or beta-heparin; Chondroitin-6-sulfate, i.e. chondroitin sulfate C; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Botany (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Materials Engineering (AREA)
  • Polymers & Plastics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicinal Preparation (AREA)
KR1020237009204A 2015-01-09 2016-01-08 콘드로이틴 황산 유도체 및 방광 질환 처치제 Active KR102655779B1 (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2015003572 2015-01-09
JPJP-P-2015-003572 2015-01-09
KR1020177021920A KR102512431B1 (ko) 2015-01-09 2016-01-08 콘드로이틴 황산 유도체 및 방광 질환 처치제
PCT/JP2016/050526 WO2016111356A1 (ja) 2015-01-09 2016-01-08 コンドロイチン硫酸誘導体及び膀胱疾患処置剤

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020177021920A Division KR102512431B1 (ko) 2015-01-09 2016-01-08 콘드로이틴 황산 유도체 및 방광 질환 처치제

Publications (2)

Publication Number Publication Date
KR20230047193A KR20230047193A (ko) 2023-04-06
KR102655779B1 true KR102655779B1 (ko) 2024-04-05

Family

ID=56356041

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020237009204A Active KR102655779B1 (ko) 2015-01-09 2016-01-08 콘드로이틴 황산 유도체 및 방광 질환 처치제
KR1020177021920A Active KR102512431B1 (ko) 2015-01-09 2016-01-08 콘드로이틴 황산 유도체 및 방광 질환 처치제

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020177021920A Active KR102512431B1 (ko) 2015-01-09 2016-01-08 콘드로이틴 황산 유도체 및 방광 질환 처치제

Country Status (8)

Country Link
US (2) US10350236B2 (cg-RX-API-DMAC7.html)
EP (2) EP3757136B1 (cg-RX-API-DMAC7.html)
JP (2) JP6026708B1 (cg-RX-API-DMAC7.html)
KR (2) KR102655779B1 (cg-RX-API-DMAC7.html)
CN (1) CN107108761B (cg-RX-API-DMAC7.html)
CA (1) CA2972866C (cg-RX-API-DMAC7.html)
ES (1) ES2828692T3 (cg-RX-API-DMAC7.html)
WO (1) WO2016111356A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10350236B2 (en) * 2015-01-09 2019-07-16 Seikagaku Corporation Chondroitin sulfate derivative and agent for treating bladder diseases
JP7660066B2 (ja) * 2019-10-03 2025-04-10 生化学工業株式会社 膀胱の粘膜下組織への医薬品有効成分の経粘膜的送達システム
RU2751649C1 (ru) * 2020-08-24 2021-07-15 Наталья Геннадиевна Галкина Способ лечения и профилактики цистита
AU2022348759A1 (en) * 2021-09-16 2024-01-25 Coval Biopharma (Shanghai) Co., Ltd. Drug delivery system for locally delivering therapeutic agents and uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006517928A (ja) * 2003-02-19 2006-08-03 ステラー・インターナシヨナル・インコーポレーテツド 高用量のコンドロイチン硫酸を用いた膀胱炎の処置

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2604930B2 (ja) * 1990-12-14 1997-04-30 株式会社ディ・ディ・エス研究所 ヒアルロン酸およびコンドロイチン誘導体
US6562781B1 (en) * 1995-11-30 2003-05-13 Hamilton Civic Hospitals Research Development Inc. Glycosaminoglycan-antithrombin III/heparin cofactor II conjugates
US6083933A (en) 1999-04-19 2000-07-04 Stellar International Inc. Treatment of cystitis-like symptoms with chondroitin sulfate following administration of a challenge solution
ITPD20020271A1 (it) * 2002-10-18 2004-04-19 Fidia Farmaceutici Composti chimico-farmaceutici costituiti da derivati dei taxani legati covalentemente all'acido ialuronico o ai suoi derivati.
CN101921347B (zh) * 2004-01-07 2014-07-30 生化学工业株式会社 透明质酸衍生物及含有其的药剂
KR20080065269A (ko) * 2005-08-03 2008-07-11 모리아 바이오파마슈티컬스 낭포성 섬유증에 대한 리피드 접합체의 용도 및 그의 적용
IE20070900A1 (en) * 2007-12-12 2009-06-24 Eurand Pharmaceuticals Ltd New anticancer conjugates
JP2015003572A (ja) 2013-06-20 2015-01-08 トヨタ紡織株式会社 乗物用シート
WO2015005459A1 (ja) * 2013-07-10 2015-01-15 生化学工業株式会社 呼吸器投与用の医薬組成物
US10098962B2 (en) 2013-07-10 2018-10-16 Seikagaku Corporation Glycosaminoglycan derivative and method for producing same
US10350236B2 (en) * 2015-01-09 2019-07-16 Seikagaku Corporation Chondroitin sulfate derivative and agent for treating bladder diseases

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006517928A (ja) * 2003-02-19 2006-08-03 ステラー・インターナシヨナル・インコーポレーテツド 高用量のコンドロイチン硫酸を用いた膀胱炎の処置

Also Published As

Publication number Publication date
EP3243841A4 (en) 2018-07-11
KR20230047193A (ko) 2023-04-06
JP2017036455A (ja) 2017-02-16
US10350236B2 (en) 2019-07-16
EP3757136B1 (en) 2023-07-19
CN107108761A (zh) 2017-08-29
JPWO2016111356A1 (ja) 2017-04-27
WO2016111356A1 (ja) 2016-07-14
US10953037B2 (en) 2021-03-23
KR20170098942A (ko) 2017-08-30
CA2972866A1 (en) 2016-07-14
JP6748551B2 (ja) 2020-09-02
ES2828692T3 (es) 2021-05-27
US20170354675A1 (en) 2017-12-14
EP3757136A1 (en) 2020-12-30
KR102512431B1 (ko) 2023-03-22
EP3243841A1 (en) 2017-11-15
CN107108761B (zh) 2020-06-30
JP6026708B1 (ja) 2016-11-16
CA2972866C (en) 2023-08-22
US20190282607A1 (en) 2019-09-19
EP3243841B1 (en) 2020-09-30

Similar Documents

Publication Publication Date Title
ES2741439T3 (es) Compuestos aromáticos sustituidos
US20260014072A1 (en) Treatment of protein aggregation myopathic and neurodegenerative diseases by parenteral administration of trehalose
US10953037B2 (en) Chondroitin sulfate derivative and agent for treating bladder diseases
JP2005533810A (ja) 新規な抗コレステロール組成物及びその使用方法
AU2017321782A1 (en) Macrophages/microglia in neuro-inflammation associated with neurodegenerative diseases
TWI564291B (zh) 一氧化氮生成調節劑
AU2018201544B2 (en) Tocopherol and tocopheryl quinone derivatives as correctors of Lysosomal Storage Disorders
JP2025094276A (ja) 膀胱の粘膜下組織への医薬品有効成分の経粘膜的送達システム、医薬組成物、及び膀胱疾患処置剤
HK40039515A (en) Chondroitin sulfate derivative and agent for treating bladder diseases
MXPA99003616A (en) Pharmaceutical preparations comprised of salts of hyaluronic acid with local anaesthetics
HK1217300B (en) Treatment of oculopharyngeal muscular dystrophy by intravenous administration of trehalose

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20230316

Application number text: 1020177021920

Filing date: 20170804

PA0201 Request for examination
PG1501 Laying open of application
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20230712

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20240110

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20240403

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20240403

End annual number: 3

Start annual number: 1

PG1601 Publication of registration